NCT04398745 A Study of Belantamab Mafodotin Monotherapy in Multiple Myeloma Participants With Normal and Varying Degree of Impaired Renal Function Status ACTIVE_NOT_RECRUITING Phase PHASE1
NCT04398680 A Study of Belantamab Mafodotin in Multiple Myeloma Participants With Normal and Impaired Hepatic Function Status WITHDRAWN Phase PHASE1
NCT04394650 A Study of CC-98633, BCMA-targeted Chimeric Antigen Receptor (CAR) T Cells, in Participants With Relapsed and/or Refractory Multiple Myeloma Status COMPLETED Phase PHASE1
NCT04392037 Iberdomide Combined With Low-dose Cyclophosphamide and Dexamethasone Status ACTIVE_NOT_RECRUITING Phase PHASE2
NCT04379817 Somatostatin Receptors Imaging in Relapsing and Refractory Multiple Myeloma Patients Status COMPLETED Phase PHASE2
NCT04376957 Pilot Study of an Oral Chemotherapy Teaching Tool to Improve Adherence in Patients With Multiple Myeloma Status UNKNOWN Phase NA
NCT04354246 COM902 (A TIGIT Inhibitor) in Subjects With Advanced Malignancies Status COMPLETED Phase PHASE1
NCT04349358 FCH vs FDG PET/CT in Detection of Lesions in Patients With Multiple Myeloma (MIM) Status RECRUITING Phase NA
NCT04322292 A Study of BCMA-directed CAR-T Cells Treatment in Subjects With r/r Multiple Myeloma Status COMPLETED Phase PHASE1
NCT04318327 BCMA-directed CAR-T Cell Therapy in Adult Patients With Multiple Myeloma Status TERMINATED Phase PHASE1
NCT04314752 Development of a Research Infrastructure for Understanding and Addressing Multiple Myeloma Disparities Status RECRUITING Phase N/A
NCT04314401 National Cancer Institute "Cancer Moonshot Biobank" Status ACTIVE_NOT_RECRUITING Phase N/A
NCT04309942 Evaluation Study on Performance of Guided Clinical Pharmacy Consultation in Patients With Multiple Myeloma on First Oral Anticancer Treatment Status COMPLETED Phase NA
NCT04309084 Natural Killer Cell (CYNK-001) Infusions in Adults With Multiple Myeloma Status UNKNOWN Phase PHASE1
NCT04303091 The Feasibility of a Physical Activity Intervention for Advanced Multiple Myeloma Patients Status COMPLETED Phase NA